cariboubio.comBioTechFounded: 2011Funding to Date: $41.55MM
Caribou Biosciences is a leading clinical-stage CRISPR genome editing biotechnology company developing an internal pipeline of off-the-shelf, genome-edited CAR-T and natural killer (NK) cell therapies.
For more details on financing and valuation for Caribou Biosciences, register or login.
Already registered? Click here to log in
To read this article and more news on Caribou Biosciences, register or login.
Already registered? Click here to log in.
Forge and SharesPost have teamed up to provide you with an enhanced trading experience.